Stephen Simpson, CFA
Long only, growth at reasonable price, value, research analyst

After The Twists And Turns, Sanofi Still A Value

It's been an interesting few days for Sanofi (SNY) and its shareholders. While the shares were thumped last week on what was seen as disappointing guidance, Monday saw a rebound on news of regulatory troubles at rival Novo Nordisk (NVO). Through it all, Sanofi still looks like a relative value and may in fact be one of the best bargains in the Big Pharma space.

Q4 Results Come In Fine, But Guidance "Disappoints"

Sanofi closed the year on a so-so note, but expectations weren't calling for particularly robust performance as the company absorbs some patent-related challenges to revenue and profits.

Revenue was flat as reported and down 2% operationally. While top-seller Lantus was up 23% in...

Join Seeking Alpha PRO to read this archived article and 11,574 other archived articles
  • Access Top Ideas, chosen by Seeking Alpha’s editors
  • Filter long and short ideas by market cap and sector
  • Get Coverage of over 5,000 stocks, many of which have little or no coverage elsewhere
"In just the first month of using PRO, I used it to generate two ideas which were actionable for me. As a result of these two positions, I have earned more than 20 times the annual subscription costs for PRO." Michael Yagemann, Greenbridge Capital
"I am pleasantly surprised with the scope of small and mid-cap coverage PRO offers. You can't find that any where else." Patrick Rice, Mainstay Capital Management
100% Satisfaction Guaranteed
Money back guarantee. Seeking Alpha PRO members receive a no-questions-asked refund for membership on months paid and not used. Details